Lay Summary: Our study suggests that replacement of vitamin D levels does not affect the severity of colds but may increase the frequency of cold symptoms in select groups of patients with asthma, particularly when the dose of ICS is being reduced. 
INTRODUCTION
Vitamin D insufficiency is common in the general population and has been linked to susceptibility to respiratory infections [1] [2] [3] [4] . Physiologically, vitamin D alters the function of multiple cell types involved in both the innate and the adaptive immune systems, modulating pathways that can participate in the response to respiratory viral infections [5] [6] [7] [8] [9] . Given the results of these epidemiologic and physiologic studies, trials have been conducted to determine whether vitamin D supplementation reduces respiratory infections, but achieved mixed results.
In children enrolled during the winter, vitamin D supplementation with 1,200 IU per day for 4 months reduced laboratory-confirmed influenza illnesses by 42% [10] . Likewise, ingestion of vitamin-D (300 IU/d)-fortified milk during the winter reduced the incidence of acute RTIs by 44%
as assessed through questionnaires of children [11] . However, monthly vitamin D doses of 100,000 IU for 18 months failed to reduce reported and laboratory-confirmed upper RTIs in adults [12] . A meta-analysis of 11 randomized controlled trials indicated that vitamin D supplementation may prevent RTIs when administered daily rather than in high doses intermittently, although heterogeneity among the trials prevented a definitive conclusion [13] .
Recently, a trial of weekly 10,000 IU of vitamin D3 for 2 months in the fall did not affect the viral load or clinical rate of colds, but reduced the incidence of laboratory-confirmed viral RTIs in healthy adults [14] . Although very few of these studies selectively enrolled patients with vitamin D insufficiency, the results collectively suggest that vitamin D supplementation may protect against RTIs, particularly when taken daily.
Patients with asthma are prone to more severe chest cold symptoms despite having similar rate of RTIs when compared to healthy co-habitants [15] . Because vitamin D insufficiency is also common in this population and may have independent effects on lung function and corticosteroid responsiveness [16] , we recently completed a trial of vitamin D supplementation in patients with asthma and baseline 25-OH-D insufficiency [17] . Vitamin D supplementation taken daily for 28 weeks did not reduce the rates of first asthma treatment failure or exacerbations, although it modestly spared the daily dose of inhaled corticosteroids (ICS) when the corticosteroid was tapered [17] . There was a trend for a reduction of the overall rate of exacerbations including multiple events per subject associated with assignment to Vitamin D supplementation (HR, 0.63 [95% CI, 0.39-1.01], P = .05). In a responder analysis, patients achieving vitamin D sufficiency at 12 weeks regardless of treatment assignment had a 40% reduction in overall exacerbations compared to placebo, with a 20% decrease noted for every 10 ng/mL improvement in 25-hydroxyvitamin D levels [17] .
Because asthma exacerbations are frequently caused by viral RTIs [15, [18] [19] [20] , we sought to determine whether vitamin D supplementation reduced severity and rate of acute RTIs (common colds) and the associated changes in asthma control in adults with mild to moderate asthma and vitamin D insufficiency. A portion of this work has been presented as a poster [21] .
METHODS

Study population
This analysis was a prospectively planned secondary analysis of a multi-center, randomized, double-blinded, placebo-controlled, clinical trial (VIDA -Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness) [17] . Briefly, 408 adult patients with mild-tomoderate asthma, baseline serum levels of 25-OH-D3 < 30 ng/mL and asthma symptoms despite low dose ICS were randomized to receive placebo or cholecalciferol for 28 weeks (100,000 IU once, then 4000 IU/d for 28 weeks) as add-on therapy in the background of a tapering ICS protocol.
Procedures
The visit structure and assessment of treatment failure, exacerbation, lung function, airway hyperresponsiveness, asthma symptoms, asthma control (measured by the Asthma Control Test (ACT) score [22] ), asthma-specific quality of life, 25-hydroxyvitamin D levels, and ICS exposure have been previously described [17] . Cold symptoms were assessed using the
21-item Wisconsin Upper Respiratory Symptom Survey (WURSS-21), a validated instrument
with a range of 0 to 140 points and a minimally important difference of 18.5 [23, 24] . Instructions on how to complete these surveys and their distribution occurred at the randomization visit, with reinforcement of its use at all subsequent visits occurring at 4 to 6 week intervals. Electronic diaries assessed asthma symptoms and asked "Did you have a cold today?", which, if answered "yes", participants were instructed to start completing WURSS-21 surveys daily. Survey completion continued until the first question on the survey ('How sick do you feel today?') was answered 'Not sick' for two days in a row. All completed surveys were returned to the study coordinator at the participant's next study visit. Each participant was given 21 copies of the WURSS-21 to keep at home in the event that he/she experienced a cold event between visits.
Melanin-dependent skin pigmentation is a measure of sun exposure, which can correlate with endogenous production of 25-OH-D [25] . Melanin levels were estimated using a Smart Probe 400 (IMS, Inc, Milford, CT), a spectrophotometer that measures degrees of pigmentation on a continuous scale from 0 to 100, 0 being absolute black and 100 being absolute white.
Pigmentation measurements were made from the forehead, outer forearm, inner upper arm and abdomen, with two readings averaged and recorded at each location. We proposed that the difference between the forearm and abdominal readings would be a surrogate measure of degree of sun exposure. Skin pigmentation was measured before and after the 28 weeks of vitamin D supplementation.
Statistical analysis
Testing the primary hypothesis regarding the effect of Vitamin D supplementation on the severity of colds was addressed by fitting a repeated measures analysis of covariance (RM-ANCOVA) model to the peak WURSS-21 cold scores during each cold, allowing for multiple colds within each participant. Assuming that the incidence of colds was similar in our study to that seen in the Asthma Clinical Research Network Post-cold Asthma Control and Exacerbation (PAX) study [24] , we estimated that 65 participants per group would experience at least one cold (32.4%). With this sample size we expected to have over 90% power to detect an effect size of 18, assuming that the power in our analyses was increased by the inclusion of multiple colds for each person (2-sided alpha 0.05, standard deviation 32).
In addition to evaluating the average peak cold score from each cold, the average score on day 1 and day 2 were also compared between the intervention and control groups. The rate of colds was compared between the treatment groups using Poisson regression. Each model included adjustment for center, African American race, and BMI>25 (similar to the parent trial was made using a RM-ANCOVA model adjusted for center, African American race, and BMI>25. All tests were two-sided with a p-value < 0.05 denoting significance. Without formal adjustment for the number of secondary analyses that were performed, the secondary results should be considered exploratory. All analyses were performed using SAS version 9.3 (SAS Institute Inc).
RESULTS
Baseline subject characteristics
Overall, 203 of the 408 (49.8%) participants experienced at least one self-reported cold during the course of the study. For subjects who developed a cold during the study, Table 1 shows the baseline characteristics prior to the cold, stratified by treatment assignment. For the original trial, there were no baseline characteristic differences noted between treatment assignments [17] . This randomization process was also successful when evaluating participants who had a cold during the course of the trial; the exceptions noted were small differences in baseline melanin (Table 1) .
Cold severity and frequency Figure 1 demonstrates the month of occurrence of the colds. The average peak WURSS-21 score for the group of subjects with colds was 61.3 (95% CI 57.6-65.0). We defined improvement of the RTI as the time until the WURSS-21 score was less than 50% of the peak value for two consecutive days [24] . The median time to improvement was 4 days with an interquartile range of 3-6 days. Participants with a cold had a decline in their ACT score (average -1.3, 95% CI -1.8 to -0.8) at the visit occurring after the cold, which was significantly different than the change in ACT scores over the course of the entire treatment period for subjects not experiencing a cold (0.2, 95% CI -0.4 to 0.8, p < 0.001, Figure 2 , left panel). The minimally important difference for the ACT Score ranges between 2 and 3 depending on the methods and population studied [26] ; having a cold increased the odds of having a decline in the ACT Score of at least 2 (OR 1.59, 95% CI 1.01 to 2.49, p = 0.043, Figure 2 , right panel).
There were no significant differences between treatment groups in the adjusted models for the WURSS-21 scores on day 1, day 2, the sum of days 1-2, the sum of days 1-4, or the sum of days 1-7 ( Figure 3A) . The time course of the WURSS-21 scores is shown in Figure 3B 
DISCUSSION
In symptomatic patients with mild-to-moderate asthma with baseline insufficiency of vitamin D and in the setting of ICS dose reduction [17] , those assigned to an effective vitamin D supplementation regimen did not have less severe or frequent colds relative to subjects receiving placebo (Figures 3) . Although this was a negative result, it is worth noting that the frequency of colds in this pre-specified analysis conferred over 90% power to observe an effect size that was smaller than the Minimal Important Difference for the survey instrument used. The observation period was slightly longer than 6 months, ensuring that each subject was followed during at least one cold season. Adjustment for season of enrollment or sun exposure did not change these results. We conclude that the lack of effect on cold severity in the overall study population is valid and unlikely to change without significant modification of the design.
A few caveats prevent broad generalizations of this study's results. These include the mild-to-moderate severity of the patient population studied. More severe patients with a history of frequent RTI-induced exacerbations might be an ideal population, with evaluation of respiratory samples during the course of the cold to confirm viral-associated events.
Additionally, the ICS tapering protocol may have had unanticipated effects. For example, we hypothesized but did not observe (17) (17)). This is also contrary in some ways to the observations that patients achieving vitamin D sufficiency have a lower overall rate of exacerbations (17) . It is unlikely that vitamin D levels have any influence on the participants' exposure to respiratory viruses. One speculation is that patients with 25-hydroxyvitamin D levels less than 20 ng/mL may be more likely than those patients with higher levels to have asymptomatic upper respiratory tract infection when exposed to common cold viruses, and in this case replacement of vitamin D could reconstitute the inflammatory responses related to symptom development. This reconstitution could lead to a greater likelihood of upper airway symptoms, while also reducing the likelihood of lower airway infection and related risk of exacerbation. Of note, the median severity of the cold symptoms on a qualitative assessment was mild. Reconciling these possibilities would likely be best addressed in an inoculation study design, before and after vitamin D supplementation. In conclusion, the statistical power, frequency of study visits and lack of a signal in the current trial suggest that longer studies or those achieving higher levels are unlikely to change the conclusion that restoration of vitamin D sufficiency does not impact cold severity in patients with mild to moderate asthma undergoing an ICS dose reduction, and may increase the rate of symptomatic colds in patients with the lowest baseline levels of vitamin D. + Median (Q1,Q3) reported ^ Geometric mean (CV) reported T T-test for differences between specified groups TL T-test for differences between specified groups on log scale W Wilcoxon rank-sum test for differences between specified groups 
